|
|
Volumn 27, Issue 3, 2001, Pages 148-150
|
|
Harm, ethics committees and the gene therapy death
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ORNITHINE CARBAMOYLTRANSFERASE;
VIRUS VECTOR;
ADENOVIRUS;
ANIMAL EXPERIMENT;
CLINICAL STUDY;
CONFLICT;
CONTROLLED STUDY;
DEATH;
EDITORIAL;
ENZYME DEFICIENCY;
FINANCE;
GENE THERAPY;
HUMAN;
IMMUNE RESPONSE;
INFORMED CONSENT;
LAW SUIT;
MEDICAL ETHICS;
MEDICAL RESEARCH;
QUALITY OF LIFE;
RISK BENEFIT ANALYSIS;
TOXICITY;
VIRUS PARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
GENETICS AND REPRODUCTION;
RESEARCH SUBJECTS;
SELECTION OF SUBJECTS;
ADOLESCENT;
CLINICAL TRIALS;
ETHICS COMMITTEES;
FATAL OUTCOME;
GENE THERAPY;
HUMAN EXPERIMENTATION;
HUMANS;
INFORMED CONSENT;
MALE;
ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE;
PATIENT SELECTION;
QUALITY-ADJUSTED LIFE YEARS;
RESEARCH SUBJECTS;
|
|
EID: 0034769433
PISSN: 03066800
EISSN: None
Source Type: Journal
DOI: 10.1136/jme.27.3.148 Document Type: Editorial |
|
Times cited : (81)
|
|
References (9)
|
